ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)Business Wire • 01/12/23
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative BiomarkersBusiness Wire • 12/27/22
Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a TurnaroundZacks Investment Research • 12/19/22
Here's Why ChromaDex (CDXC) is Poised for a Turnaround After Losing 7.5% in 4 WeeksZacks Investment Research • 12/16/22
ChromaDex Reports FDA's Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United StatesBusiness Wire • 11/11/22
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022Business Wire • 10/26/22
ChromaDex's Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo's (NHNE) Prestigious Nutrition Planet AwardsBusiness Wire • 10/24/22
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million InvestmentBusiness Wire • 10/11/22
ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection FractionBusiness Wire • 10/04/22
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common StockBusiness Wire • 10/03/22
Sinopharm Xingsha to Introduce ChromaDex's Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)Business Wire • 09/19/22
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into BrazilBusiness Wire • 09/01/22
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex's Intellectual Property Held Under Exclusive License From Dartmouth CollegeBusiness Wire • 08/15/22
ChromaDex Corporation (CDXC) CEO Robert Fried on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022Business Wire • 08/02/22
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)Business Wire • 07/07/22
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)Business Wire • 06/15/22